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462a Tuesday, February 10, 2015of TM1A helix would not protrude into the membrane core. To further char-
acterize the conformation of the TM1A helix, we used SMD simulations and
pulled this helix relative to the scaffold or the core domain. The free energy
profile was also endorsed our findings in the position of TM1A. These study
indicates that changes in the environment can affect the equilibrium confor-
mation of LeuT.
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The existence of a solved structure for a dopamine transporter drastically
changes the landscape for investigation of the mechanism of monoamine trans-
porter function. While previous structures for LeuT have shed light on transport
mechanisms, and though LeuT shares considerable structural overlap with
dDAT, LeuT has no corresponding electrophysiology. The new structure there-
fore has the advantage of correlating structure and function to help unravel the
outstanding mystery of transporters as channels, which has well developed cor-
relates in the ClC class of Cl- channels but no equivalent in monoamine
transporters.
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Dopamine transporter (DAT) controls neurotransmitter dopamine homeostasis
by pumping excess extracellular (EC) dopamine into presynaptic neurons to pre-
vent neurotoxicity. The process is assisted by co-transport of two sodiumand one
chloride ions.Malfunction ofDAThas been implicated inmanydiseases, such as
Parkinson’s disease and attention deficit hyperactivity disorder. Significant ad-
vances have been made in the characterization of the structure and dynamics
of a prokaryotic orthologue, LeuT, although the molecular mechanism of dopa-
mine translocation through human DAT (hDAT) remains elusive. Recently, the
first eukaryotic DAT structure was resolved from Drosophila melanogaster, in
the outward-facing open (OFo) state. Using homology modeling and unbiased
molecular dynamics simulations, we elucidated the sequence of molecular
events involved in dopamine translocation by hDAT, including the uptake
from the EC medium, closure of the EC gates upon dopamine binding, passage
over a holo-occluded intermediate temporarily stabilized via concerted changes
in the relative orientations of the TMhelices, subsequent opening of the intracel-
lular vestibule, release of co-transported ions, and succeeding discharge of dopa-
mine uponweakening the electrostatic attractions by aspartates near the binding-
site. The transport events revealedby these hDATsimulations showstriking con-
sistency with those disclosed in recent investigation of LeuT transport cycle (1,
2). The study sheds light for the first time at the mechanism of DAT functioning
at the atomic level and provides insights intomethods for modulating its interac-
tions with drugs and other substrate proteins.
1. Cheng, M.H. and I. Bahar. 2014. Complete mapping of substrate transloca-
tion highlights the role of LeuT N-terminal segment in regulating transport cy-
cle, PLoS Comput Biol. in press.
2. Cheng, M.H. and I. Bahar. 2013. Coupled global and local changes direct
substrate translocation by neurotransmitter-sodium symporter ortholog LeuT,
Biophys J. 105:630-9.
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In recent work, we employed a series of methylenedioxypyrovalerone (MDPV)
analogs to determine the structural determinants for the potent nature of MDPV
to inhibit uptake by the human dopamine transporter (hDAT). In hDAT-
expressing Xenopus laevis oocytes clamped to60 mV, MDPV and its analogs
induced comparable outward currents (attributed to a block of the endogenous
hDAT inward leak) that did not return to the original baseline after washout.
We recorded DA-induced hDAT currents before and after application of either
MDPV or its analogs, and obtained individual amplitude recovery profiles rela-
tive to the initial DA-induced currents, which correlated with the compounds’
potency to inhibit DA uptake via hDAT. Interestingly, for all compounds, afterwashout of the second DA application, the hDAT-mediated shift in baseline re-
turned to the elevated level. Moreover, for two MDPV analogs the second DA
response recovered 100% of the first DA response even if the baseline had
shifted. Furthermore, the shift in baseline produced by one of these analogs
was not impeded by the presence of a high concentration of dopamine. These
results suggest two distinct sites of action for drugs targeting DAT. We em-
ployed electrophysiology to characterize this secondary site of action, and ho-
mology models of hDAT based on the crystal structure of a bacterial leucine
transporter (LeuT) combined with docking simulations to identify the second-
ary binding site of MDPV and MDPV analogs.
Support: NIH 5R01DA033930-03 and 3R01DA033930-02S1
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The uptake and storage of neurotransmitters in synaptic vesicles is carried out by
neurotransmitter transporters from, e.g., the vesicular monoamine transporter
(VMAT) family, which allow regulated release of monoamines from the presyn-
aptic neuron into the synaptic cleft. Phylogenetic analysis reveals that VMAT
proteins are evolutionarily related to bacterial multidrug transporters involved
in antibiotic resistance. In fact, VMATs are responsible for sequestering toxic
substrates such as MPPþ into vesicles, away from their primary site of action.
To understand the molecular mechanisms of transport by VMAT, we character-
ized a homologous transporter fromBrevibacillus brevis (BbMAT)usingmolec-
ular modeling and biochemical approaches. First, we built a homologymodel of
BbMAT based on the crystal structure of YajR, a putative proton-driven MFS
transporter fromEscherichia coli. As expected, themodel contains 12 transmem-
brane (TM) helices, arranged in two domains of 6TMs each,which are related by
2-fold pseudo-symmetry around an axis perpendicular to themembrane between
the twohalves. Themodel predicts that four carboxyl residues, a histidine, and an
arginine are located in the TM segments that line the central cavity. The activity
of BbMAT coupled to a proton gradient was assessed biochemically, demon-
strating that the transport process is electrogenic and therefore that at least two
protons are exchanged for each substrate. The six residues exposed to the
aqueous cavity according to themodel were thenmutated either alone or in com-
bination, and these mutants were tested for their ability to confer resistance to
ethidium and acriflavine. The results show that only two residues, D25 (TM1)
and E229 (TM7), are essential for proton-coupled transport in BbMAT. We
conclude that BbMAT is a paradigm for the study of multidrug and neurotrans-
mitter transport by VMATs.
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Monoamine transporters take up neurotransmitters, but they also release neuro-
transmitters when challenged by abused drugs like amphetamine (AMPH) or
MDMA (ecstasy). Transported substrates including transmitters and drugs
are accompanied by excess positive charges that constitute an inward, depola-
rizing current. Previous research suggests that dopamine transporter (DAT)
substrate-induced currents produce bursts of action potentials in dopaminergic
neurons. Both pace-making and action potential bursting are mediated by L-
type Ca2þ channels (CaV1.3) in several excitable cells, including some dopa-
minergic neurons, whereas N-type Ca2þ channels (CaV2.2) are mainly
involved in neurotransmitter release. Here we test the hypothesis that mono-
amine transporters are electrically coupled to L-type Ca2þ channels. We ex-
press the serotonin transporter (SERT) in wt and CaV1.1-null myoblasts.
After differentiation, wt myotubes, but not CaV1.1-null myotubes, release
Ca2þ after 5HT or S(þ)MDMA exposure, suggesting the participation of L-
type Ca2þ channels. This effect was sensitive to fluoxetine but refractory to
TTX, implicating SERT and excluding the participation of voltage-gated
Naþ channels. Furthermore, co-expression of SERT & CaV1.3 in HEK cells
supported Ca2þ signals, whereas SERT & CaV2.2 was unresponsive to 5HT
or S(þ)MDMA. Similarly, co-expression of DAT & CaV1.3 or DAT &
CaV1.2 supported Ca2þ signals induced by S(þ)AMPH or dopamine, whereas
DAT & CaV2.2 expression was refractory to both agents even though S(þ)
